Detail akcie Catalyst Pharm online

Business Summary: Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Catalyst Pharmaceuticals Inc revenues increased 86% to $398.2M. Net income decreased 14% to $71.4M. Revenues reflect License and other revenue increase from $265K to $1.7M. Net income was offset by reasear increase from $18.1M to $91.7M (expense), Selling, general and adminis - Balancing increase from $52M to $120.9M (expense).